Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
- DOI
- 10.1016/s0140-6736(20)30748-0
- Published
- 2020 Jul 11
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-20-30748-0,
title = {Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.},
author = {Vaduganathan M and Claggett BL and Jhund PS and Cunningham JW and Pedro Ferreira J and Zannad F and Packer M and Fonarow GC and McMurray JJV and Solomon SD},
year = {2020},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(20)30748-0},
url = {https://doi.org/10.1016/s0140-6736(20)30748-0}
}RIS
TY - JOUR TI - Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. AU - Vaduganathan M AU - Claggett BL AU - Jhund PS AU - Cunningham JW AU - Pedro Ferreira J AU - Zannad F AU - Packer M AU - Fonarow GC AU - McMurray JJV AU - Solomon SD PY - 2020 JO - Lancet (London, England) DO - 10.1016/s0140-6736(20)30748-0 UR - https://doi.org/10.1016/s0140-6736(20)30748-0 ER -
APA
M, V., BL, C., PS, J., JW, C., J, P. F., F, Z., M, P., GC, F., JJV, M., & SD, S. (2020). Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(20)30748-0
Source records
- pubmed · retrieved 2026-09-26T01:23:42.376Z